J Trauma Nurs by Baird, Janette et al.
Evaluation of a Safer Opioid Prescribing Protocol (SOPP) for 
Patients Being Discharged from a Trauma Service
Janette Baird,
Associate Professor of Emergency Medicine, The Warren Alpert School of Medicine of Brown 
University, Injury prevention Center, Rhode Island Hospital, Providence, RI, USA
Mark Faul,
Senior Health Scientist, Centers for Disease Control and Prevention, Atlanta, GA, USA
Traci C Green,
Deputy Director, Boston Medical Center Injury Center, Boston University School of Medicine, 
Department of Emergency Medicine, Boston, MA, USA, Associate Professor of Emergency 
Medicine and Epidemiology, The Warren Alpert School of Medicine of Brown University, Rhode 
Island Hospital, Providence, RI, USA
Jonathan Howland,
Professor Department of Emergency Medicine, Boston University School of Medicine, Boston 
Medical Center Injury Prevention Center, Boston, MA, USA
Charles A Adams,
Rhode Island Hospital, Chief, Division of Trauma and Surgical Critical Care, Department of 
Surgery, Providence, RI, USA
Melinda J Hodne,
Rhode Island Hospital, University Surgical Associates, Inc., Providence, RI, USA
Nie Bohlen,
Rhode Island Hospital, Department of Surgery, Providence, RI, USA
Michael J Mello
Injury Prevention Center at Rhode Island Hospital, Department of Emergency Medicine, Warren 
Alpert Medical School of Brown University, Department of Health Services, Practice and Policy, 
Brown University School of Public Health, Providence, RI, USA
Abstract
The aims of this study were to evaluate the effects on opioid medication prescribing, patient opioid 
safety education, and prescribing of naloxone following implementation of a safer opioid 
prescribing practice protocol (SOPP) as part of the electronic health record (EHR) system at a 
Level I Trauma Center.
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This was a prospective observational study of the EHR of trauma patients pre (n = 191) and post (n 
= 316) SOPP implementation; between 2014 and 2016. At a comparison Level I trauma site not 
implementing SOPP, EHR for the same time period were assessed for any historical trends in 
opioid and naloxone prescribing.
After SOPP implementation, the implementation site increased the use of non-narcotic pain 
medication; decreased dispensing high opioid dose (≥ 100 MME), significantly increased the 
delivery of opioid safety education to patients and initiated prescribing naloxone. These changes 
were not found in the comparison site
Opioid prescribing for acute pain can be effectively reduced in a busy trauma setting with a 
guideline intervention incorporated into an EHR. Guidelines can increase the use of non-narcotic 
medications for the treatment of acute pain and increase naloxone co-prescription for patients with 
a higher risk of overdose.
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BACKGROUND
Although there has been an increase globally in opioid prescribing the United States has the 
world’s highest rate of dispensing opioid analgesic medications (Berterame et al., 2016), 
with a prescribing rate in 2017 of 58.5 opioid prescriptions per 100 of the population and 
with individuals receiving on average 3.4 prescriptions per annum (Centers for Disease 
Control and Prevention, 2017). Although most patients who are prescribed opioid 
medications do not misuse them, the increase in the use of these drugs presents a potentially 
serious risk to patient safety, due to the risk of medication misuse, addiction and overdose 
(Centers for Disease Control and Prevention, 2012). Opioid prescribing practices are an 
important focus as a mechanism for reducing this serious public health issue.
Factors associated with misuse, abuse and addiction to opioids include an ongoing or history 
of a substance abuse disorder, undiagnosed or untreated psychiatric disorder, age 25-34, 
traumatic experience (Rosenthal et al., 2018), and social or family factors associated with 
substance use disorder (Webster et al., 2011). Access to prescribed opioids, dose and 
continued prescribing of opioids has also been linked to misuse (Sehgal, Manchikanti, & 
Smith, 2012). Patients prescribed opioid pain medication with pre-existing medical co-
morbidities such as renal and hepatic diseases, respiratory disease, congestive heart failure, 
and psychiatric disorders have an increased risk of opioid overdose (Darke, Kaye, & Duflou, 
2006; Wyne, Rai, Cuerden, Clark, & Suri, 2011). Other situational factors such as co-
prescription of an opioid with benzodiazepines or other sedative drugs (O’Brien et al., 
2017), and concurrent or recent use of alcohol or other drugs (Kandel, Hu, Griesler, & Wall, 
2017), are also predictive of increase risk of opioid overdose (Sun et al., 2017). Additionally, 
an increased risk of fatal opioid overdose has also been associated with high daily doses of 
opioids, defined as daily intake at or exceeding 100 milligram morphine equivalent (MME) 
dose (Bohnert et al., 2011)
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The use of opioid medication for pain management during admission and on discharge from 
trauma care is almost ubiquitous (Wunsch, Wijeysundera, Passarella, & Neuman, 2016). 
Recent research has found that among injured trauma patients discharged to home with 
prescribed opioids, continued use of prescription opioids four-months after discharge could 
be predicted from the amount of continued pain experienced and the patients’ self-reported 
ability to cope with their pain (Rosenbloom, McCartney, Canzian, Kreder, & Katz, 2017). 
Field and colleagues, reported that the non-medical use of prescription opioids by injured at-
risk drinkers continued for up to 12 months following discharge from a Level I trauma care 
facility. They also found that pre-admission non-medical use of prescription opioids and/or 
other drug misuse was predictive of non-prescribed opioid use following discharge (Field, 
Cochran, Caetano, Foreman, & Brown, 2014). While estimates of substance misuse are 
around 8.4% in the general population (Lipari & Van Horn, 2013), among injured patients 
this rises to between 40 and 60% (Alam et al., 2012).
The Centers for Disease Control and Prevention (CDC) guidelines for opioid prescribing for 
chronic pain (Dowell, Haegerich, & Chou, 2016) include: avoiding high daily dose (i.e. daily 
dose ≥ 90 Morphine Milligram Equivalent [MME; – the metric used to define the potency of 
an opioid dose, which allows us to compare potency across different types of prescribed 
opioids] (Eder et al., 2005)); co-prescription with naloxone (an effective opioid agonist that 
can reverse overdose) for daily dose ≥ 50 MME (or for any opioid overdose risk factors); 
avoiding co-prescription of benzodiazepines; and combining opioids with non-
pharmacological and non-opioid therapy. Other recommendations include limiting the 
number of days of prescribing for acute pain and assessing patients’ total opioid use before 
repeat prescribing. The challenge, for the health care professional in a trauma setting, is to 
adequately control acute pain without increasing the burden of misuse, morbidity, and 
mortality among those prescribed opioid analgesics.
PURPOSE
The primary objective of the current study was to evaluate the Safer Opioid Prescribing 
Practice (SOPP) protocol implemented at a Level 1 trauma center for patients discharged to 
home with a prescription for opioid medication after an inpatient admission
RESEARCH QUESTIONS
Does the implementation of a SOPP protocol increase patient education around opioid 
medication, and increase naloxone prescribing for patients at increased risk for an opioid 
overdose? Additionally, does a SOPP protocol reduce prescribed MME opioid dose at 
discharge and increase the use of non-opioid pain management approaches?
METHODS
Study sample
This study was conducted at a Level I adult trauma center in New England that admits over 
2,900 adult patients annually. Study data and reporting were handled in accordance with the 
guideline on the Transparent Reporting of Evaluations with Nonrandomized Designs (Des 
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Jarlais, Lyles, Crepaz, & Group). The Institutional Review Board at the site approved the 
study protocol and provided a waiver of informed patient consent for the EHR data 
extraction.
The EHR of patients admitted and discharged to home from the SOPP implementation site 
between July 1, 2014 and May 31, 2016 were included. Study inclusion criteria were: patient 
discharged to home; discharged with a prescription for opioid analgesic medication; age ≥ 
18. Exclusion criteria were age < 18 years and discharged to continued care services other 
than patients’ home.
Patient EHR across the same time period was extracted from a Level I trauma center from a 
nearby New England state to determine if changes in the implementation site were due to 
historical factors, that influenced the opioid prescribing practices at a site not exposed to 
SOPP implementation. This comparison trauma center site admits approximately 1,800 adult 
patients annually.
Measures
The data for the EHR review were collected for three non-sequential patient cohorts, each of 
three-month’s duration: cohort 1: July 1, 2014 to September 30, 2014, representing pre-
SOPP implementation; cohort 2: September 1 to November 30, 2015, representing early 
SOPP implementation, and cohort 3: March 1 to May 31, 2016, representing the 
maintenance phase of SOPP.
We extracted the following information from patients’ EHRs at each of these three-time 
points: patient demographic information; admission history, including primary diagnosis; 
injury severity; length of hospital inpatient stay; medication on discharge; home medication; 
and, comorbid medical conditions. The opioid MME discharge dose was calculated by 
multiplying the frequency of daily dose by the strength of dose (or maximum, if a range of 
frequency was recorded). A classification system for drug types of discharge and home 
medication (opioid analgesic, benzodiazepines, other sedatives, and non-opioid analgesic) 
was developed by the research study pharmacist.
The study investigators developed the data extraction procedures and the principal 
investigator trained the research assistants (RAs) in this protocol. The protocol, training 
approaches and validation approaches have previously been reported (Baird et al., 2017).
From the extracted EHR, an opioid risk factor score was developed based on prior research. 
(Dunn et al., 2010; Green, Grau, Carver, Kinzly, & Heimer, 2011; Silva, Schrager, 
Kecojevic, & Lankenau, 2013; Webster et al., 2011) The following risk factors were scored 
as present 1, versus not present or not documented 0: a. comorbid medical condition risk 
(COPD, congestive heart failure, end stage renal or liver disease); b. prior to admission home 
medication risk (opioid and/or benzodiazepine medication); c. discharge benzodiazepine co-
prescription risk; d. discharge opioid medication ≥ 100 MME risk (MME dose was 
calculated for the discharge opioid dose by multiplying the frequency of daily dose by the 
strength of dose or maximum if a range of frequency was recorded).; e. positive illicit drug 
toxicology on admission or positive alcohol behavioral screen; f. prior treatment for 
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substance use disorder in past 12 months; and, g. opioid overdose in the past 12 months. The 
summed opioid overdose risk score potential range was 0 to 7. The number of doses of 
opioid analgesic medication as well as the use of non-narcotic medication prescribed were 
also collected.
SOPP Implementation
The SOPP protocol was developed as part of clinical care, and integrated into the 
implementation site’s EHR, and functioned as an electronic best practice alert (BPA), 
triggered when a trauma patient was discharged to home with an opioid medication. The 
trauma staff (prescribers and nurses) were trained in the SOPP protocol and BPA prior to the 
implementation. The prescriber BPA displayed a pre-calculated table that presented the 
maximum daily MME of the opioid prescribed at discharge. The prescriber indicated if the 
discharge dose was ≥ 100 MME. If affirmed, or if there was another identified risk factor, 
the prescriber was advised to prescribe naloxone. If naloxone was not prescribed, a reason 
for this was requested. A link to the state Prescription Drug Monitoring Program was also 
made available.
Following the prescriber BPA, the nurse discharging the patient also received up to two 
BPAs. First, a universal BPA indicated that the nurse should provide opioid medication safe 
use education to all patients discharged with a prescribed opioid. Patient brochures were 
developed to standardize this education about safe use of opioid medication (i.e. not using 
with alcohol, using only amount prescribed, not using with other medications unless 
medically advised); safe storage of opioids, and information on safer disposal of unused 
opioids. If the patient was prescribed naloxone, the second BPA was implemented. In this 
BPA, the nurse printed a patient education brochure on overdose recognition and 
administration of naloxone. The nurse was also prompted to use the naloxone demonstration 
kits with the patient and their family member to provide a visual aid for instructing how to 
administer naloxone. All educational materials were available in English, Spanish, and 
Portuguese.
Data analysis
Statistical power analysis was performed to estimate the required number of EHRs of 
eligible patients to be reviewed to identify at least one identified opioid overdose risk factor 
in at least 30% of the reviewed charts. A minimum of 161 EHRs pre and post 
implementation was required to detect this preponderance of opioid overdose risk; this 
assumed a 5% error in our estimated proportion of positive charts.
The data were imported into Statistical Analysis Software (SAS) (Version 9.4, Carey, NC) 
for analyses. For descriptive analyses, means, counts and proportions are reported with 95% 
confidence intervals (CIs) (Laupacis, Sackett, & Roberts), and medians with inter-quartile 
range (IQR). The inter-rater reliability of the extracted EHR data was calculated using 
Cohen’s Kappa. The rater agreement coefficients were determined for six identified 
categories: patient demographics, comorbid medical conditions, positive toxicology or 
substance use screen, home medication, discharge medications, and discharge opioid 
medication MME. These agreement rates are reported with 95% CIs.
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The focus of the analyses was on changes in clinical practice related to the BPA at the SOPP 
implementation trauma site. The data from the comparison site were used to determine if 
changes at the implementation site were attributable to historical or secular trends, rather 
than the SOPP protocol. We compared the frequency and change in frequency (with 95% 
CIs) of naloxone prescribing and opioid safety education across the three-time cohorts.
To address the secondary aim of the study we examined change in the discharge prescribing 
across two metrics: medication dosage (odds dichotomized as < 100 MME daily and ≥ 100 
MME daily), and number of opioid analgesic pills dispensed, as well as the use of non-
opioid pain management approaches. A logistic regression, adjusting for gender, age and 
injury severity, was conducted to estimate the change in likelihood of receiving a higher 
medication dosage following SOPP implementation.
RESULTS
Rater Agreement
Across the three patient EHR data collection cohorts, collapsed across both sites, the inter-
rater agreement were: a. patient descriptive data = 100%; b. comorbid medical conditions = 
(kappa 0.93 95% CI =.0.89, 0.97; c. positive substance use screen (kappa = 0..83, 95% CI = 
0.78, 0.88.); d. home medications = (kappa=0.94, 95% CI= .0.91 ,.0.98); e. discharge 
medications type= (kappa =1.00); and, f. discharge medication MME ≥ 100 (kappa = 0.89, 
95% CI=0.85, 0.93).
Patient Characteristics
Table 1 details the characteristics of the patients observed across cohorts at the SOPP 
implementation site. Most were male, white and not Hispanic. The median length of stay for 
the trauma admission was 3 days for all cohorts; length of stay ranged from 1 to 49 days; the 
three most common injury mechanisms for the admitted trauma patients were motor vehicle 
crash (34.5%), falls (34.1%), or cutting/piercing (18.1%), with these mechanisms accounting 
for 87% of all admissions. Median length of stay at the comparison site was also 3 days and 
79% of admissions were due to motor vehicle crash, falls, or cutting/piercing.
Opioid safety education and naloxone prescribing
A substantial proportion of patients across the cohorts at the implementation site had at least 
one of the seven defined opioid overdose risk factors (Table 2). The most frequently 
identified risk factors were the discharge opioid medication dose ≥ 100 MME, and positive 
screen for alcohol or drug use at the time of admission. After the implementation of SOPP, 
prescribers’ response rate to the MME dose alert in the EHR was 92% for patients 
discharged with an opioid for cohort 2 and 99% of cohort 3 patients (Table 3).
Table 3 indicates the outcome of the BPA for naloxone co-prescribing, patient opioid safety 
education given, and education provided if naloxone was prescribed. We found that the BPA 
identified 23 patients from cohort 2 that had an opioid risk factor resulting in 21 
prescriptions for naloxone given (91%), and 11 naloxone BPAs for cohort 3 with 11 
prescriptions for naloxone given (100%). Nurses documented they trained 12 patients on 
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naloxone use in cohort 2 who were prescribed naloxone (57%) and trained five of the 
patients prescribed naloxone in cohort 3 (45%). For the 168 patients discharged during 
cohort 2 we found EHR documentation of a nurse led opioid safety education being 
provided to 58 patients (34.5%) and for 57 of the 150 patients discharged to home with an 
opioid prescription for cohort 3 (38%).
Prescribed Opioid Dose and Pain Management
At the implementation site, 94% of cohort 1 trauma patients were discharged to home with a 
prescription for opioid medication; this decreased to 89% for cohort 2 and 84 % for cohort 3 
(Table 4: Δ = 10% 95% CI: 5, 15%). The most commonly prescribed discharge opioid 
analgesic medication was oxycodone, at a 5mg dose and a frequency of up to four-hourly as 
needed, across sites and cohorts (Table 4); the median number of pills prescribed also 
significantly decreased. The median dose of 90MME did not change after SOPP 
implementation; however, the likelihood of a prescribed dose ≥100MME at discharge did 
significantly decrease (AOR = 0.36; 95%CI; 0.18, 0.72). The use of non-narcotic medication 
prescribed for pain control at the implementation site significantly increased after SOPP; 
cohort 1 73% to 93% (cohort 3) (Δ = 18%; 95% CI: 13; 23).
Comparison Site
At the comparison site the proportion of patients who were discharged home with a 
prescription for opioid medication remained consistently lower than at the implementation 
site across the three cohorts, at between 62-63% (p = 0.02) but did not change over time. 
There were site differences in the median MME discharge dose: the intervention site 
prescribed a median of 90 MME at all cohorts, while the comparison site prescribed a 
median of 45 MME, across all cohorts. The proportion of patients discharged to home with a 
high dose of opioids (≥ 100MME) did not change across the cohorts at the comparison site. 
The proportion of patients discharged to home with a non-opioid pain medication also 
increased at the comparison site across the cohorts (Δ = 13%; 95% CI: 9; 17) but was 
significantly less than at the SOPP implementation site. No patient opioid safety education 
or co-prescription for naloxone was found in the review of the EHR at the comparison site 
across the time-periods of the study.
DISCUSSION
The purpose of this study was to evaluate implementation of clinical protocol for opioid 
prescribing, SOPP, at a Level I Trauma Center. There is evidence that the SOPP protocol 
changed practices within the implementation Trauma Center site by decreasing the number 
of prescription that had a high daily dose of opioids (≥100 MME), the quantity of opioids 
prescribed at discharge, prescribing naloxone to patients with an identified opioid overdose 
risk, and in providing safer opioid medication use education to trauma patients. These 
effects were found, when we compared the Trauma Center initiating the SOPP protocol 
across time, and in comparison, to a Trauma Center site not utilizing this protocol.
Positive steps to decrease both the quantity and dose of opioids prescribed have been 
advocated by many institutions as essential to reduce the morbidity and mortality associated 
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with prescribed opioid use (Dowell et al., 2016; Sehgal et al., 2012). Increasing patient 
accesses to the opioid reversal medication, naloxone, through provider co-prescribing has 
also been recommended (Davis, Ruiz, Glynn, Picariello, & Walley, 2014; Dowell et al., 
2016; Doyon, Aks, & Schaeffer, 2014). The results of the SOPP implementation evaluation 
study indicates that the EHR can be utilized to identify patients risk factors for opioid 
overdose, and that a clinical protocol for trauma service prescribers and medical staff can be 
in implemented in response to those risks. These results were consistent with other opioid 
guideline and opioid reduction prescribing efforts (Fulton-Kehoe et al., 2015) and current 
state guidelines recommend lower upper limits for opioid prescribing. However, our data 
also demonstrated that there is room for improvement given the number of patients who did 
not receive all or some of the elements of the BPAs that comprise the SOPP protocol.
The BPA for identifying patients with an opioid overdose risk factor used EHR information 
that was easily available but was not always consistent with the information found during the 
extraction of EHR data by the RAs. Research staff were able to extensively review all 
available data fields, such that information on a patient’s past substance use disorder history 
that may not be documented in the physician’s or nurse’s record, may have been found in 
the notes of the social worker or psychiatrist conducting consultation.
The BPA was designed to use data fields readily available to the physician or nurse who 
wanted to check any medical information, and the differences between the identification of 
patients through the BPA versus the RA review may indicate either an over-inclusion of the 
research review or the limits of a BPA based only on electronic record review. Also, the 
prescriber may have discussed naloxone with the patient who refused it being prescribed; but 
this was not documented. The BPA alerted the physician that the patient had an opioid 
overdose risk and that naloxone prescribing should be considered, but the specific risk type 
was not given, and if the prescribed dose was < 100 MME the prescriber may have evaluated 
the risk as less than was indicated by the BPA. Similarly, the nursing BPA was triggered to 
provide patients general safety education about prescribed opioid use, yet less than 60% 
were documented as receiving the education. This may represent poor documentation or 
discomfort of the nursing staff in delivering opioid safety and naloxone use education to 
patients.
Future analyses could explore the reasons for these differences between the BPA responses 
and data extracted from the EHR to determine the potential provider perceptions that 
underpin naloxone prescribing.
LIMITATIONS
This was an evaluation of a new clinical protocol for patients discharged from the trauma 
services of a busy urban Level I Trauma Center. As patients were not randomized to receive 
the SOPP intervention differences in patient characteristics and medical practices at the two 
sites may have contributed to the differences found in prescribing practices and may have 
affected the internal validity and conclusions of this study. Also, there were changes in 
recommendations for opioid prescribing that were being developed by the implementation 
site state Department of Health during the period of SOPP implementation that could have 
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confounded these results. Although these prescribing regulations were not instituted into 
practice until after the final cohort of data collection had been completed; knowledge of 
these impending changes could have affected opioid prescribing.
CONCLUSIONS
In summary, the SOPP study demonstrated that the additional BPA to identify patients at 
risk for harm from their opioid medication could be integrated into an existing EHR system. 
This safety protocol was successfully used to identify patients at increased risk for opioid 
overdose and provide general education around safer prescribed opioid use for these 
discharged patients. More work is needed to improve the frequency at which these services 
can be provided to trauma patients who are prescribed opioids. These findings have 
important implication for shaping public health policy decisions on opioid prescribing safety 
across health care services.
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KEY POINTS
• Opioid prescribing is almost ubiquitous among severely injured trauma 
patients
• An EHR guided intervention can reduce high dose prescribing of opioid pain 
medications, increase patient medication education, and increase co-
prescribing of naloxone.
• Further studies are needed to evaluate approaches to increases the issue of 
safer opioid prescribing practices across patient groups
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Table 1:
Demographic characteristics of Trauma Patients at SOPP Implementation Site
Demographic characteristics Cohort 1
n = 191
Cohort 2
n = 166
Cohort 3
n = 150
Median age, years (IQR), range 43 (25, 60)18-96
45 (28, 58)
18-93
47 (30,62)
18-94
Female n (%) 43 (22.5) 55 (32.7) 32 (20.7)
Hispanic n (%) 22 (11.5) 26 (15.5) 21 (14)
White n (%) 148 (77.5) 119 (71.7) 108 (72)
Black/African-American n (%) 19 (10) 17 (10.2) 12 (8)
Other n (%) 24 (12.5) 30 (18.1) 30 (20)
J Trauma Nurs. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Baird et al. Page 14
Table 2:
Opioid Overdose Risk Factors Across SOPP Implementation Cohorts
Risk Factor Type n (%) Cohort 1
N = 191
Cohort 2
N=168
Cohort 3
N= 150
1. Medical co-morbidity 29 (15.2) 38 (22.6) 32 (21.3)
2. Prior Treatment Past 12 months
Alcohol/Substance 8 (4.2) 9 (5.4) 5 (3.3)
Major psychiatric disorder 0 3 (1.7) 2 (1.3)
3. Opioid 0verdose past 12 months 0 1 (< 1) 0
4. Pre-admission home medication (opioid/benzodiazepine 45 (23.6) 30 (17.9) 38 (25.3)
5. Discharge opioid ≥ 100MME daily 53 (27.7) 45 (26.7) 40 (26.6)
6. Benzodiazepine co-prescribed at discharge 18 (9.4) 11 (6.5) 26 (17.3)
7. Positive for alcohol and/or drug screen on admission 126 (66) 91 (54.2) 94 (62.7)
Calculated unintentional opioid overdose risk factors
0 =79 (41.4)
1= 76 (38)
2= 22 (10.7)
3= 3 (11)
4= 1 (7.3)
>4 = 0
0 =37 (22)
1= 64 (38.1)
2= 30 (18)
3= 24 (14.3)
4= 7 (4.2)
5= 6 (3.6)
> 6 = 0
0 =40 (26.7)
1= 62 (41.3)
2= 36 (24)
3= 10 (6.7)
4= 6 (4)
5= 2 (1)
> 5 = 0
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Table 3.
Best Practice Alert Response Cohort 2 and 3 at SOPP Implementation Site
Cohort 2 N = 168 Cohort 3 N = 150
*MME Table responded to by prescriber n (%) 155 (92) 149 (99)
BPA alert for daily MME ≥ 100 or other risk factor n (%) 23 (14.4%) 11 (7.4%)
Naloxone prescribed if indicated 21 (91) 11 (100)
BPA opioid safety education n (%) 58 (34.5) 57 (35)
BPA naloxone education (if prescribed) n (%) 12 (57) 5 (45)
*
Prescriber had to indicate if MME table indicated prescribed discharge dose of opioid ≥ 100 Morphine Milligram Equivalent (MME)
*
BPA = Best Practice Alert
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Table 4:
Opioid Medication at Discharge at SOPP Implementation Site
Discharge Medication Cohort 1 Cohort 2 Cohort 3
Implementation Site n = 191 n=168 n= 150
Frequent Rx Type/Dose (%) Oxycodone/5 mg (87.8) Oxycodone/5 mg (70.3) Oxycodone/5 mg (77.3)
Median daily MME opioid discharge dose (IQR) 90 (45,120) 90 (45,120) 90 (45,120)
Median number dispensed (IQR) 60 (30,60) 50 (30,60) 40 (30,60)
Frequency of non-narcotic pain medication n (%) 144 (75) 151 (90) 139 (93)
Rx = Prescription; IQR=interquartile range
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